Literature DB >> 15013059

Lipopolysaccharide retards development of amygdala kindling but does not affect fully-kindled seizures in rats.

Mohammad Sayyah1, Iraj Toubeihaye Najafabadi, Siamak Beheshti, Sayeh Majzoob.   

Abstract

Seizures are common sequel to brain insults in cases such as stroke, trauma and infection where there is a certain neuroinflammation. Intracerebroventricular (i.c.v.) administration of lipopolysaccharide (LPS) induces an inflammatory state in brain that is used as a model of neuroinflammation. We studied the effect of LPS (0.25 and 2.5 microg/rat, i.c.v.) on development of electrical kindling of the amygdala and on fully-kindled seizures. LPS, at the doses used, had no effect on fully-kindled seizures and afterdischarge (AD) duration at 0.5, 2 or 4h after administration. However, daily injection of LPS (2.5 microg/rat) retarded acquisition of kindled behavioral seizures. This antiepileptogenic effect could be due to the release of inflammatory mediators from microglia and the related morphological and functional changes in synaptic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15013059     DOI: 10.1016/j.eplepsyres.2003.11.002

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  9 in total

1.  CD40-CD40 Ligand Pathway is a Major Component of Acute Neuroinflammation and Contributes to Long-term Cognitive Dysfunction after Sepsis.

Authors:  Monique Michels; Lucinéia Gainski Danieslki; Andriele Vieira; Drielly Florentino; Dhébora Dall'Igna; Letícia Galant; Beatriz Sonai; Francieli Vuolo; Franciele Mina; Bruna Pescador; Diogo Dominguini; Tatiana Barichello; João Quevedo; Felipe Dal-Pizzol; Fabrícia Petronilho
Journal:  Mol Med       Date:  2015-03-26       Impact factor: 6.354

2.  Microglial ablation and lipopolysaccharide preconditioning affects pilocarpine-induced seizures in mice.

Authors:  Martine M Mirrione; Dorothy K Konomos; Iordanis Gravanis; Stephen L Dewey; Adriano Aguzzi; Frank L Heppner; Stella E Tsirka
Journal:  Neurobiol Dis       Date:  2010-04-09       Impact factor: 5.996

3.  Platelet-activating factor receptor antagonism targets neuroinflammation in experimental epilepsy.

Authors:  Alberto E Musto; Mark Samii
Journal:  Epilepsia       Date:  2011-01-04       Impact factor: 5.864

4.  Regional sensitivity to neuroinflammation: in vivo and in vitro studies.

Authors:  Sigal Liraz-Zaltsman; Alexander G Alexandrovich; Victoria Trembovler; Ianai Fishbein; Rami Yaka; Esther Shohami; Anat Biegon
Journal:  Synapse       Date:  2011-02-25       Impact factor: 2.562

5.  Intra-hippocampal injection of lipopolysaccharide inhibits kindled seizures and retards kindling rate in adult rats.

Authors:  Amin Ahmadi; Mohammad Sayyah; Baharak Khoshkholgh-Sima; Samira Choopani; Jafar Kazemi; Mehdi Sadegh; Farshad Moradpour; Hossein Nahrevanian
Journal:  Exp Brain Res       Date:  2013-02-01       Impact factor: 1.972

6.  Effect of chronic intracerebroventricluar administration of lipopolysaccharide on connexin43 protein expression in rat hippocampus.

Authors:  Mohammad Sayyah; Bahar Kaviani; Baharak Khoshkholgh-Sima; Marzieh Bagheri; Maryam Olad; Samira Choopani; Reza Mahdian
Journal:  Iran Biomed J       Date:  2012

7.  Mechanisms of long-term cognitive dysfunction of sepsis: from blood-borne leukocytes to glial cells.

Authors:  Monique Michels; Amanda V Steckert; João Quevedo; Tatiana Barichello; Felipe Dal-Pizzol
Journal:  Intensive Care Med Exp       Date:  2015-10-29

Review 8.  The role of microglia in diabetic retinopathy.

Authors:  Jeffery G Grigsby; Sandra M Cardona; Cindy E Pouw; Alberto Muniz; Andrew S Mendiola; Andrew T C Tsin; Donald M Allen; Astrid E Cardona
Journal:  J Ophthalmol       Date:  2014-08-31       Impact factor: 1.909

9.  Acute lipopolysaccharide exposure facilitates epileptiform activity via enhanced excitatory synaptic transmission and neuronal excitability in vitro.

Authors:  Fei Gao; Zhiqiang Liu; Wei Ren; Wen Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-16       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.